CG Oncology (CGON) Director Leonard Post Sells 1,000 Shares After Option Exercise

What Happened

• Leonard E. Post, a director of CG Oncology (CGON), exercised stock options and sold shares on Aug 14, 2026. The Form 4 shows an exercise (M) of 1,000 shares at $0.60 (cost $600) and an open‑market sale of 1,000 shares at $74.54 for proceeds of $74,540. The filing also lists a separate derivative conversion/disposition of 1,000 shares at $0.00 in the same reporting period. Overall, this was primarily a sale executed under a preexisting plan rather than an unsolicited market sale.

Key Details

• Transaction date: 2026-08-14
• Exercise: 1,000 shares at $0.60 per share (acquired; $600 total)
• Sale: 1,000 shares at $74.54 per share (disposed; $74,540 total)
• Additional entry: 1,000-share derivative conversion/disposition reported at $0.00 (see note below)
• Shares owned after transaction: Not specified in the provided summary of the filing
• Footnotes: F1 — sale effected pursuant to a Rule 10b5‑1 trading plan adopted March 5, 2026; F2 — instruments were fully vested
• Timeliness: Form filed 2026-08-18 for a 2026-08-14 transaction; filing appears timely (within required business-day window)

Context

• The combo of an option exercise and same-day sale often reflects a cashless exercise or planned disposition; here the sale was executed under a 10b5‑1 plan (prearranged trading plan), which is commonly used to avoid trading on nonpublic information. The zero-dollar derivative disposal reported alongside the exercise likely reflects a conversion/administrative reporting entry tied to the exercise—check the full Form 4 for transaction flow and any broker/tax withholding details. This is a director sale under a planned program and not necessarily an indicator of new, unplanned sentiment.